A rational approach to selecting and ranking some pharmaceuticals of concern for the aquatic environment and their relative importance compared with other chemicals

Aquatic organisms can be exposed to thousands of chemicals discharged by the human population. Many of these chemicals are considered disruptive to aquatic wildlife, and the literature on the impacts of these chemicals grows daily. However, because time and resources are not infinite, research must focus on the chemicals that represent the greatest threat. One group of chemicals of increasing concern is pharmaceuticals, for which the primary challenge is to identify which represent the greatest threat. In the present study, a list of 12 pharmaceuticals was compiled based on scoring the prevalence of different compounds from previous prioritization reviews. These included rankings based on prescription data, environmental concentrations, predicted environmental concentration/predicted no‐effect concentration (PEC/PNEC) ratios, persistency/bioaccumulation/(eco)toxicity (PBT), and fish plasma model approaches. The most frequently cited were diclofenac, paracetamol, ibuprofen, carbamazepine, naproxen, atenolol, ethinyl estradiol, aspirin, fluoxetine, propranolol, metoprolol, and sulfamethoxazole. For each pharmaceutical, literature on effect concentrations was compiled and compared with river concentrations in the United Kingdom. The pharmaceuticals were ranked by degree of difference between the median effect and median river concentrations. Ethinyl estradiol was ranked as the highest concern, followed by fluoxetine, propranolol, and paracetamol. The relative risk of these pharmaceuticals was compared with those of metals and some persistent organic pollutants. Pharmaceuticals appear to be less of a threat to aquatic organisms than some metals (Cu, Al, Zn) and triclosan, using this ranking approach. Environ Toxicol Chem 2016;35:1021–1027. © 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC.

[1]  J. Sumpter,et al.  Assessing the concentrations and risks of toxicity from the antibiotics ciprofloxacin, sulfamethoxazole, trimethoprim and erythromycin in European rivers. , 2015, The Science of the total environment.

[2]  E. Kristiansson,et al.  Assessing variation in the potential susceptibility of fish to pharmaceuticals, considering evolutionary differences in their physiology and ecology , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[3]  J. Sumpter,et al.  Putting pharmaceuticals into the wider context of challenges to fish populations in rivers , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[4]  D. G. Joakim Larsson,et al.  Pollution from drug manufacturing: review and perspectives , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[5]  J. Sumpter,et al.  Using risk-ranking of metals to identify which poses the greatest threat to freshwater organisms in the UK. , 2014, Environmental pollution.

[6]  P. Fong,et al.  The biological effects of antidepressants on the molluscs and crustaceans: a review. , 2014, Aquatic toxicology.

[7]  Bryan W Brooks,et al.  An exploratory investigation of various modes of action and potential adverse outcomes of fluoxetine in marine mussels. , 2014, Aquatic toxicology.

[8]  Richard J. Williams,et al.  Worldwide estimation of river concentrations of any chemical originating from sewage-treatment plants using dilution factors , 2013, Environmental toxicology and chemistry.

[9]  Christian G Daughton,et al.  The Matthew Effect and widely prescribed pharmaceuticals lacking environmental monitoring: case study of an exposure-assessment vulnerability. , 2014, The Science of the total environment.

[10]  J. Sumpter,et al.  Are some invertebrates exquisitely sensitive to the human pharmaceutical fluoxetine? , 2014, Aquatic toxicology.

[11]  John P. Sumpter,et al.  The Read-Across Hypothesis and Environmental Risk Assessment of Pharmaceuticals , 2013, Environmental science & technology.

[12]  Lee E. Brown,et al.  Global Synthesis and Critical Evaluation of Pharmaceutical Data Sets Collected from River Systems , 2012, Environmental science & technology.

[13]  C Rudén,et al.  Prioritising pharmaceuticals for environmental risk assessment: Towards adequate and feasible first-tier selection. , 2012, The Science of the total environment.

[14]  Rolf Altenburger,et al.  Using the fish plasma model for comparative hazard identification for pharmaceuticals in the environment by extrapolation from human therapeutic data. , 2011, Regulatory toxicology and pharmacology : RTP.

[15]  D. Zwart,et al.  Ecological Relevance of Key Toxicants in Aquatic Systems , 2011 .

[16]  John P. Sumpter,et al.  Pharmaceuticals in the Aquatic Environment: Steroids and Anti-Steroids as High Priorities for Research , 2010 .

[17]  Mats Tysklind,et al.  Predicted critical environmental concentrations for 500 pharmaceuticals. , 2010, Regulatory toxicology and pharmacology : RTP.

[18]  A. Johnson.  Natural variations in flow are critical in determining concentrations of point source contaminants in rivers: an estrogen example. , 2010, Environmental science & technology.

[19]  Bryan W Brooks,et al.  Leveraging mammalian pharmaceutical toxicology and pharmacology data to predict chronic fish responses to pharmaceuticals. , 2010, Toxicology letters.

[20]  A. Boxall,et al.  Occurrence and fate of human pharmaceuticals in the environment. , 2010, Reviews of environmental contamination and toxicology.

[21]  John P Sumpter,et al.  Protecting aquatic organisms from chemicals: the harsh realities , 2009, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[22]  Anders Baun,et al.  Probabilistic environmental risk characterization of pharmaceuticals in sewage treatment plant discharges. , 2009, Chemosphere.

[23]  Andrew C Johnson,et al.  A national risk assessment for intersex in fish arising from steroid estrogens , 2009, Environmental toxicology and chemistry.

[24]  Werner Brack,et al.  Toward a Holistic and Risk-Based Management of European River Basins , 2009, Integrated environmental assessment and management.

[25]  E. Cooper,et al.  Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment. , 2008, The Science of the total environment.

[26]  M. Carballa,et al.  Comparison of predicted and measured concentrations of selected pharmaceuticals, fragrances and hormones in Spanish sewage. , 2008, Chemosphere.

[27]  Erik Kristiansson,et al.  Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. , 2008, Environmental science & technology.

[28]  F. Baquero,et al.  Antibiotics and antibiotic resistance in water environments. , 2008, Current opinion in biotechnology.

[29]  Jeanne Garric,et al.  Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation. , 2008, Toxicology letters.

[30]  Karen A Kidd,et al.  Collapse of a fish population after exposure to a synthetic estrogen , 2007, Proceedings of the National Academy of Sciences.

[31]  A M J Ragas,et al.  Human and environmental risk assessment of pharmaceuticals: differences, similarities, lessons from toxicology , 2007, Analytical and bioanalytical chemistry.

[32]  A. M. Christensen,et al.  Mixture and single‐substance toxicity of selective serotonin reuptake inhibitors toward algae and crustaceans , 2007, Environmental toxicology and chemistry.

[33]  Anna-Karin Johansson,et al.  Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients. , 2006, The Science of the total environment.

[34]  Thomas Knacker,et al.  Evaluation of Measured and Predicted Environmental Concentrations of Selected Human Pharmaceuticals and Personal Care Products (10 pp) , 2006, Environmental science and pollution research international.

[35]  A. Pollio,et al.  Environmental risk assessment of six human pharmaceuticals: Are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment? , 2004, Environmental toxicology and chemistry.

[36]  Hans Sanderson,et al.  Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. , 2004, Regulatory toxicology and pharmacology : RTP.

[37]  Aleem Ahmed Khan,et al.  Diclofenac residues as the cause of vulture population decline in Pakistan , 2004, Nature.

[38]  C. Tyler,et al.  Comparative responses of molluscs and fish to environmental estrogens and an estrogenic effluent. , 2003, Aquatic toxicology.

[39]  K. Thomasb,et al.  Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom , 2004 .

[40]  Jacob K Stanley,et al.  Aquatic ecotoxicology of fluoxetine. , 2003, Toxicology letters.

[41]  Oliver A.H. Jones,et al.  Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. , 2002, Water research.

[42]  M. Birkved,et al.  Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. , 2000, Chemosphere.

[43]  T. Ternes.  Occurrence of drugs in German sewage treatment plants and rivers 1 Dedicated to Professor Dr. Klaus , 1998 .

[44]  J. Sumpter,et al.  Vitellogenesis as a biomarker for estrogenic contamination of the aquatic environment. , 1995, Environmental health perspectives.